Management of hydatidosis in children. Twenty-one year experience

G Mavridis1, E Livaditi, G Christopoulos-Geroulanos

  • 12nd Department of Pediatric Surgery, Aghia Sophia Children's Hospital, 79 Alevizatou Street, Papagou, Goudi-Athens, Greece. mavridig@yahoo.gr

Insights

Surgical intervention is recommended for hydatid cysts larger than 6 cm, especially in the liver, to avoid complications. While medical treatment shows promise for pulmonary hydatidosis, surgical management ensures better outcomes for larger cysts.

Area of Science:

  • Pediatric Surgery
  • Infectious Diseases
  • Parasitology

Background:

  • Hydatidosis poses a significant health challenge in non-endemic regions due to immigration.
  • Effective management strategies for pediatric hydatidosis are crucial.

Purpose of the Study:

  • To review the clinical experience in managing pediatric hydatidosis.
  • To establish criteria for optimal treatment models.

Main Methods:

  • Retrospective analysis of 150 children treated for pulmonary and abdominal hydatidosis (Echinococcus cysticosis) from 1985-2006.
  • Evaluation of medical (antihelminthic agents) versus surgical (cyst excision, partial capsectomy) treatment outcomes.
  • Analysis of cyst location: liver (82), lungs (59), spleen (4), mesentery (2), kidneys (2), pelvic floor (1).

Main Results:

  • Medical treatment failure occurred in 43.2% of liver hydatidosis cases and 30.6% of pulmonary cases.
  • Pulmonary hydatidosis patients unresponsive to medical treatment developed complications requiring surgery.
  • Surgery had a low complication rate (5.3%), with reoperation needed in only 4 cases.
  • Cyst diameter exceeding 6 cm correlated with inadequate response to medical treatment or complications.

Conclusions:

  • Medical treatment is not advised for hydatid cysts larger than 6 cm.
  • Pulmonary hydatidosis may respond better to medical therapy, but failure necessitates surgery due to high complication risk.
  • Large hydatid cysts warrant primary surgical management to ensure favorable outcomes.
Abstract

Related Concept Videos

Toxoplasmosis01:28

Toxoplasmosis

Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
Amebiasis01:28

Amebiasis

Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
American Trypanosomiasis01:22

American Trypanosomiasis

Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...